NYSEAMERICAN:ATNM Actinium Pharmaceuticals (ATNM) Stock Price, News & Analysis → Like Tiny Crypto Retirement Funds (From Crypto 101 Media) (Ad) Free ATNM Stock Alerts $6.50 -0.25 (-3.70%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$6.35▼$6.9850-Day Range N/A52-Week Range$4.00▼$9.56Volume259,950 shsAverage Volume199,931 shsMarket Capitalization$180.44 millionP/E RatioN/ADividend YieldN/APrice Target$26.15 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort Interest Get Actinium Pharmaceuticals alerts: Email Address Actinium Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside302.3% Upside$26.15 Price TargetShort InterestBearish6.48% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.16Based on 14 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.06) to ($1.81) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.53 out of 5 stars 3.5 Analyst's Opinion Consensus RatingActinium Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $26.15, Actinium Pharmaceuticals has a forecasted upside of 302.3% from its current price of $6.50.Amount of Analyst CoverageActinium Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.48% of the outstanding shares of Actinium Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverActinium Pharmaceuticals has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in Actinium Pharmaceuticals has recently decreased by 3.23%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldActinium Pharmaceuticals does not currently pay a dividend.Dividend GrowthActinium Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATNM. Previous Next 2.9 News and Social Media Coverage News SentimentActinium Pharmaceuticals has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Actinium Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest34 people have searched for ATNM on MarketBeat in the last 30 days. This is an increase of 62% compared to the previous 30 days.MarketBeat Follows9 people have added Actinium Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 350% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Actinium Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.00% of the stock of Actinium Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 22.38% of the stock of Actinium Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Actinium Pharmaceuticals are expected to grow in the coming year, from ($2.06) to ($1.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Actinium Pharmaceuticals is -3.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Actinium Pharmaceuticals is -3.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioActinium Pharmaceuticals has a P/B Ratio of 2.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingAI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… ]click here to watch a free presentation where I reveal all the details of this lucrative opportunit About Actinium Pharmaceuticals Stock (NYSEAMERICAN:ATNM)Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple targets in oncology and hematology, including CD45, CD33, HER3, and other. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company is based in New York, New York.Read More ATNM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATNM Stock News HeadlinesMarch 16, 2024 | venturebeat.comForge’s API raises bar for player rewards and engagementMarch 15, 2024 | finanznachrichten.deEuroapi: Full-year 2024 guidance suspended due to the temporary pause of API production at the Brindisi site in ItalyMarch 19, 2024 | Behind the Markets (Ad)The only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.March 15, 2024 | investorplace.comHigh-Risk, High-Reward: Little-Known Biotech Stock ATNM Could Soar on Breakthrough Cancer TreatmentMarch 14, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM) and P3 Health Partners (PIII)March 14, 2024 | msn.comKimanis records unhealthy API of 155 amid localised firesMarch 14, 2024 | finance.yahoo.comForge Launches API for Game Developers to Engage and Reward Players for Their Ongoing Play and Add Battle Pass-like Features to GamesMarch 14, 2024 | globenewswire.comPanTera signs a second agreement for the supply of actinium-225March 19, 2024 | InvestorPlace (Ad)They said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.March 13, 2024 | finance.yahoo.comUpwind Introduces API Security Solution With Real-Time Insights at the Runtime LevelMarch 13, 2024 | tmcnet.comMikMak Launches Latest Platform Enhancements Including Headless Commerce API and Custom AnalyticsMarch 12, 2024 | msn.comUS oil inventories in surprise slump last week: APIMarch 12, 2024 | tmcnet.comDeepgram Launches Aura, a Text-to-Speech API for Real-Time, Conversational Voice AI AgentsMarch 12, 2024 | finance.yahoo.comGlobal API Management Market Size is Estimated to Reach USD 7.02 billion by 2030, Growing at a CAGR of 22.15%: Straits ResearchMarch 12, 2024 | finance.yahoo.comPTV Logistics Announces Launch of PTV Developer OptiFlow API to Help Customers Reduce Costs and EmissionsMarch 12, 2024 | americanbankingnews.comActinium Pharmaceuticals (NYSEAMERICAN:ATNM) Upgraded to "Hold" by StockNews.comMarch 11, 2024 | markets.businessinsider.comBuy Rating Affirmed: Strategic Advances and Clinical Potential Bolster Actinium Pharmaceuticals’ OutlookMarch 11, 2024 | yahoo.comAfter losing access to Twitter's API, Block Party pivots to privacyMarch 11, 2024 | msn.comGoogle Marketing Platform launches new API with enhanced capabilitiesMarch 11, 2024 | msn.comTruffles To Market: Red Light Holland Wants To Develop Psilocybin API At ScaleMarch 11, 2024 | msn.comAPI sprawl: navigating the web of connectivity and security challengesMarch 11, 2024 | tmcnet.comFlash News: OKX DEX API Integrated By NovaX, a Move-to-Earn Fitness AppMarch 11, 2024 | finance.yahoo.comActinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market DemandFebruary 28, 2024 | seekingalpha.comActinium Pharmaceuticals: Closer To Realizing Its Potential (Rating Upgrade)February 28, 2024 | markets.businessinsider.comIomab-B’s Breakthrough Potential in AML Treatment Bolsters Buy Rating for Actinium PharmaceuticalsFebruary 28, 2024 | markets.businessinsider.comBuy Rating Justified by Actinium Pharmaceuticals’ Iomab-B Clinical and Commercial PromiseFebruary 27, 2024 | msn.comActinium shares surge on promising data for AML radiotherapy candidateSee More Headlines Receive ATNM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Actinium Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/03/2023Today3/18/2024Next Earnings (Estimated)3/31/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSEAMERICAN:ATNM Previous SymbolAMEX:ATNM CUSIPN/A CIKN/A Webwww.actiniumpharmaceuticals.com Phone(646) 677-3870FaxN/AEmployees49Year FoundedN/APrice Target and Rating Average Stock Price Target$26.15 High Stock Price Target$50.00 Low Stock Price Target$11.60 Potential Upside/Downside+302.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-33,020,000.00 Net MarginsN/A Pretax Margin-102,975.55% Return on Equity-91.02% Return on Assets-49.62% Debt Debt-to-Equity RatioN/A Current Ratio9.87 Quick Ratio9.87 Sales & Book Value Annual Sales$1.03 million Price / Sales175.18 Cash FlowN/A Price / Cash FlowN/A Book Value$2.61 per share Price / Book2.49Miscellaneous Outstanding Shares27,760,000Free Float26,653,000Market Cap$180.44 million OptionableNot Optionable Beta0.01 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Sandesh C. Seth M.B.A. (Age 60)M.S., Chairman & CEO Comp: $1.15MMr. Steven O'Loughlin BS (Age 38)CFO & Corporate Secretary Comp: $585kDr. Paul Diamond Esq.Ph.D., Vice President of Patent & Legal CounselDr. David GouldSenior Vice President of Corporate Development & Corporate AffairsDr. Bernie Cunningham P.M.P.Ph.D., Executive Director of Clinical Supply Chain & Logistics and CMC Project ManagementDr. Qing LiangVP & Head of Radiation SciencesDr. Avinash Desai M.D.Chief Medical OfficerMs. Jenny HsiehChief Strategy OfficerMs. Sunitha LakshminarayananSenior VP, Head of CMC & Product DevelopmentMs. Elaina HaeuberVP & Head of Clinical OperationsMore ExecutivesKey CompetitorsCapricor TherapeuticsNASDAQ:CAPROrganigramNASDAQ:OGITrevi TherapeuticsNASDAQ:TRVICybinNYSEAMERICAN:CYBNGeneluxNASDAQ:GNLXView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 22,664 shares on 3/11/2024Ownership: 4.914%Goldman Sachs Group Inc.Sold 30,864 shares on 3/1/2024Ownership: 0.056%Virtu Financial LLCBought 19,570 shares on 2/26/2024Ownership: 0.070%Bridgeway Capital Management LLCBought 20,000 shares on 2/15/2024Ownership: 0.302%Citadel Advisors LLCSold 20,200 shares on 2/15/2024Ownership: 0.000%View All Institutional Transactions ATNM Stock Analysis - Frequently Asked Questions Should I buy or sell Actinium Pharmaceuticals stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Actinium Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ATNM shares. View ATNM analyst ratings or view top-rated stocks. What is Actinium Pharmaceuticals' stock price target for 2024? 3 equities research analysts have issued 1-year target prices for Actinium Pharmaceuticals' shares. Their ATNM share price targets range from $11.60 to $50.00. On average, they expect the company's share price to reach $26.15 in the next twelve months. This suggests a possible upside of 302.3% from the stock's current price. View analysts price targets for ATNM or view top-rated stocks among Wall Street analysts. How have ATNM shares performed in 2024? Actinium Pharmaceuticals' stock was trading at $5.24 at the start of the year. Since then, ATNM stock has increased by 24.0% and is now trading at $6.50. View the best growth stocks for 2024 here. When is Actinium Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Sunday, March 31st 2024. View our ATNM earnings forecast. How were Actinium Pharmaceuticals' earnings last quarter? Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) posted its earnings results on Monday, April, 3rd. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.41) by $0.01. When did Actinium Pharmaceuticals' stock split? Actinium Pharmaceuticals shares reverse split on Tuesday, August 11th 2020. The 1-30 reverse split was announced on Monday, August 10th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 10th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of Actinium Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Actinium Pharmaceuticals investors own include OHR Pharmaceutical (OHRP), Fitbit (FIT), Global Ship Lease (GSL), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Aeterna Zentaris (AEZS) and Bionano Genomics (BNGO). Who are Actinium Pharmaceuticals' major shareholders? Actinium Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.91%), Vanguard Group Inc. (4.91%), Northern Trust Corp (0.82%), Dimensional Fund Advisors LP (0.53%), Bridgeway Capital Management LLC (0.30%) and Barclays PLC (0.14%). View institutional ownership trends. How do I buy shares of Actinium Pharmaceuticals? Shares of ATNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:ATNM) was last updated on 3/19/2024 by MarketBeat.com Staff From Our Partners8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThe world’s greatest investmentPorter & CompanyStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actinium Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.